model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20141015-not-sort-thing-you-d-work-given-choice.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}}

Of course. Here is a thorough, hindsight-informed analysis of Derek Lowe's 2014 article about quinone-based SETD8 inhibitors.

### 1. SUMMARY

The blog post is a sharp critique of a research paper that presented three quinone-containing compounds as selective inhibitors of the epigenetic enzyme SETD8. Author and medicinal chemist Derek Lowe channels the deep-seated skepticism of the drug discovery community toward quinones. He explains that quinones are broadly considered "PAINS" (Pan-Assay Interference Compounds) because their chemical reactivity—redox activity, Michael acceptor behavior, and reactivity with amines—leads to promiscuous false positives and cellular toxicity. He argues that these liabilities make them unreliable as either drug leads or as "chemical genetic tools" to understand a protein's biological function.

Lowe’s chief objections focus on the paper's central claim: that using all three quinone inhibitors collectively can "offset their off-target effects" by revealing only the phenotypes (like cell cycle arrest) common to all three. He dismantles this logic, pointing out that each compound already had a history of inhibiting other, unrelated enzymes (like CDKs and phosphatases), providing clear evidence of their promiscuity. Lowe concludes that the observed effects are impossible to attribute confidently to SETD8 inhibition and that these compounds are more likely to "confuse things more rather than throwing light on common mechanisms."

### 2. HISTORY

The subsequent decade was not kind to the specific compounds discussed in the 2014 paper, but it saw a dramatic shift in the overall perception of targeting SETD8.

First, Derek Lowe’s core critique was validated. The three quinone compounds (**NSC663284**, **BVT948**, and **ryuvidine**) were never widely adopted as chemical probes for SETD8. They failed to appear in canonical chemical probe resources like the Structural Genomics Consortium's (SGC) probe library, a gold standard for well-validated, selective chemical tools. Their reputation as promiscuous, "warhead"-containing PAINS persisted, and the strategy of using a cocktail of unselective compounds to define on-target biology was largely abandoned as flawed.

However, Lowe's general wariness about targeting SETD8 was overshadowed by major breakthroughs. The fundamental problem he identified—the lack of a good tool compound—was solved spectacularly. In 2016, the SGC published a paper introducing **UNC3866**, a peptide-based macrocycle and the first potent, selective, and cell-active chemical probe for SETD8. This compound binds to the enzyme with high affinity and, crucially, shows >1000-fold selectivity over other methyltransferases and a wide range of other potential off-targets. Its development was a landmark achievement that demonstrated SETD8 was indeed a "druggable" target. The probe became available to researchers worldwide, instantly relegating the quinone compounds to historical footnotes.

The availability of UNC3866 unlocked a flood of research into the biological roles of SETD8. This work has implicated the enzyme in numerous critical cellular processes, including DNA damage repair, genomic stability, and cell cycle regulation, cementing its role as a high-value therapeutic target in diseases like cancer.

### 3. PREDICTIONS

Lowe’s predictions were a mix of the exceptionally accurate and the inadvertently conservative.

**What he got right:**
*   **The futility of the quinones:** His prediction that these compounds would be useless as selective tools and would "use up any more time and money" was entirely correct. They were never adopted as chemical probes by the scientific community.
*   **The flawed logic of the study:** His critique that the compounds' shared phenotypes were more likely due to shared, non-selective toxicity rather than SETD8 inhibition was astute and validated by subsequent research that prioritized high selectivity.
*   **The application of medicinal chemistry principles:** He correctly identified that the authors were downplaying the most problematic feature—the quinone moiety. His argument that being "structurally distinct except for their venom-filled fangs" is not a virtue has become a foundational principle in modern hit-to-lead and probe development efforts.

**What he didn't foresee:**
*   **The rapid success in drugging the target:** The article's skeptical tone implicitly cast doubt on the entire enterprise of finding a good SETD8 inhibitor. Lowe did not predict that within just two years, a world-class chemical probe (UNC3866) would be developed that would revolutionize the field.
*   **The shift from small, "drug-like" molecules to macrocycles:** His final note—"such characterization, along with a good deal of chemistry effort, might result in derivatives that have a decent chance of hitting SETD8"—envisioned a path forward for the quinone chemical scaffolds. The solution, when it arrived, was not an optimized derivative but a structurally and mechanistically different class of molecule (a macrocycle) that specifically bound the protein-protein interaction surface of SETD8, a target once considered "undruggable." This highlights a common underestimation in drug discovery: the breakthroughs often come from orthogonal approaches, not just incremental optimization.

### 4. INTEREST

**Score: 8**

This article ranks in the top 20% for long-term interest. While its topic is highly specific, its significance is profound because it serves as a timeless educational case study in medicinal chemistry and scientific rigor.

Its long-term importance lies not in the flawed paper it critiques, but in the clarity of the principles Lowe defends. The post is a masterclass in deconstructing hype and applying deeply skeptical, medicinal-chemistry-first thinking to academic drug discovery. It perfectly captures the cultural and scientific disconnect between a "publish-first" attitude and the painstaking, cautious approach required to create truly useful chemical tools for biology. It remains a must-read for students and researchers in chemical biology, serving as a "cautionary tale" for what makes a good probe versus a "polluted" one. The article's legacy is its role in articulating the high standards required for interpreting complex biological phenotypes using small molecules, a lesson that remains as relevant today as it was in 2014.